Literature DB >> 24132641

A peptide antagonist of ErbB receptors, Inherbin3, induces neurite outgrowth from rat cerebellar granule neurons through ErbB1 inhibition.

Ruodan Xu1, Stanislava Pankratova, Søren Hofman Christiansen, David Woldbye, Anne Højland, Elisabeth Bock, Vladimir Berezin.   

Abstract

ErbB receptors not only function in cancer, but are also key developmental regulators in the nervous system. We previously identified an ErbB1 peptide antagonist, Inherbin3, that is capable of inhibiting tumor growth in vitro and in vivo. In this study, we found that inhibition of ErbB1 kinase activity and activation of ErbB4 by NRG-1β induced neurite extension, suggesting that ErbB1 and ErbB4 act as negative and positive regulators, respectively, of the neuritogenic response. Inherbin3, inhibited activation not only of ErbB1 but also of ErbB4 in primary neurons, strongly induced neurite outgrowth in rat cerebellar granule neurons, indicating that this effect mainly was due to inhibition of ErbB1 activation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24132641     DOI: 10.1007/s11064-013-1166-1

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  30 in total

Review 1.  Neuregulin signaling via erbB receptor assemblies in the nervous system.

Authors:  Sean Murphy; Randy Krainock; Muly Tham
Journal:  Mol Neurobiol       Date:  2002-02       Impact factor: 5.590

2.  Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation.

Authors:  K Elenius; S Paul; G Allison; J Sun; M Klagsbrun
Journal:  EMBO J       Date:  1997-03-17       Impact factor: 11.598

Review 3.  ERBB receptors and cancer: the complexity of targeted inhibitors.

Authors:  Nancy E Hynes; Heidi A Lane
Journal:  Nat Rev Cancer       Date:  2005-05       Impact factor: 60.716

Review 4.  Epidermal growth factor receptor antagonists and CNS axon regeneration: mechanisms and controversies.

Authors:  Martin Berry; Zubair Ahmed; Michael R Douglas; Ann Logan
Journal:  Brain Res Bull       Date:  2010-08-13       Impact factor: 4.077

Review 5.  The ErbB receptors and their ligands in cancer: an overview.

Authors:  N Normanno; C Bianco; L Strizzi; M Mancino; M R Maiello; A De Luca; F Caponigro; D S Salomon
Journal:  Curr Drug Targets       Date:  2005-05       Impact factor: 3.465

6.  A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific tissue distribution and differential processing in response to phorbol ester.

Authors:  K Elenius; G Corfas; S Paul; C J Choi; C Rio; G D Plowman; M Klagsbrun
Journal:  J Biol Chem       Date:  1997-10-17       Impact factor: 5.157

7.  Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor.

Authors:  M Gassmann; F Casagranda; D Orioli; H Simon; C Lai; R Klein; G Lemke
Journal:  Nature       Date:  1995-11-23       Impact factor: 49.962

Review 8.  The role of epidermal growth factor and its receptors in mammalian CNS.

Authors:  Richard Wing Chuen Wong; Laurent Guillaud
Journal:  Cytokine Growth Factor Rev       Date:  2004 Apr-Jun       Impact factor: 7.638

9.  A peptide antagonist of the ErbB1 receptor inhibits receptor activation, tumor cell growth and migration in vitro and xenograft tumor growth in vivo.

Authors:  Ruodan Xu; Gro Klitgaard Povlsen; Vladislav Soroka; Elisabeth Bock; Vladimir Berezin
Journal:  Cell Oncol       Date:  2010-01-01       Impact factor: 6.730

Review 10.  Requirements for a lead compound to become a clinical candidate.

Authors:  Franz F Hefti
Journal:  BMC Neurosci       Date:  2008-12-10       Impact factor: 3.288

View more
  2 in total

1.  RegenBase: a knowledge base of spinal cord injury biology for translational research.

Authors:  Alison Callahan; Saminda W Abeyruwan; Hassan Al-Ali; Kunie Sakurai; Adam R Ferguson; Phillip G Popovich; Nigam H Shah; Ubbo Visser; John L Bixby; Vance P Lemmon
Journal:  Database (Oxford)       Date:  2016-04-07       Impact factor: 3.451

2.  Dual functionalized brain-targeting nanoinhibitors restrain temozolomide-resistant glioma via attenuating EGFR and MET signaling pathways.

Authors:  Xiangqi Meng; Yu Zhao; Bo Han; Caijun Zha; Yangong Zhang; Ziwei Li; Pengfei Wu; Tengfei Qi; Chuanlu Jiang; Yang Liu; Jinquan Cai
Journal:  Nat Commun       Date:  2020-01-30       Impact factor: 14.919

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.